{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:01:27Z","timestamp":1780509687098,"version":"3.54.1"},"reference-count":52,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["febs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Molecular Oncology"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    Prostate cancer (PCa) is the second leading cause of cancer\u2010related death among men in the United States. While organ\u2010confined disease has a reasonable expectation of cure, metastatic PCa is universally fatal upon recurrence during hormone therapy, a stage termed castration\u2010resistant prostate cancer (CRPC). Until such time as molecularly defined subtypes can be identified and targeted using precision medicine, it is necessary to investigate new therapies that may apply to the entire CRPC population. The use of ascorbate, more commonly known as ascorbic acid or Vitamin C, has demonstrated antitumor activity in a variety of cancer cell types. There are several mechanisms currently under investigation to explain how ascorbate exerts anticancer effects. A simplified model depicts ascorbate as a pro\u2010drug for reactive oxygen species (ROS), which accumulate intracellularly and generate DNA damage. It was therefore hypothesized that poly (ADP\u2010ribose) polymerase (PARP) inhibitors, by inhibiting DNA damage repair, would augment the toxicity of ascorbate, leading to improved antitumor effects. Two distinct CRPC models were found to be sensitive to physiologically relevant doses of ascorbate. Moreover, additional studies indicate that ascorbate inhibits CRPC growth\n                    <jats:italic>in vitro<\/jats:italic>\n                    via multiple mechanisms including disruption of cellular energy dynamics and accumulation of DNA damage. Combination studies were performed in CRPC models with ascorbate in conjunction with escalating doses of three different PARP inhibitors (niraparib, olaparib, and talazoparib). The addition of ascorbate augmented the toxicity of all three PARP inhibitors and proved synergistic effects with olaparib in both CRPC models. Finally, the combination of olaparib and ascorbate was tested\n                    <jats:italic>in vivo<\/jats:italic>\n                    in both castrated and noncastrated models. In both cohorts, the combination treatment significantly delayed tumor growth compared to monotherapy or untreated control. These data indicate that pharmacological ascorbate is an effective monotherapy at physiological concentrations and kills CRPC cells. Ascorbate\u2010induced tumor cell death was associated with disruption of cellular energy dynamics and accumulation of DNA damage. The addition of PARP inhibition increased the extent of DNA damage and proved effective at slowing CRPC growth both\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    . These findings implicate ascorbate and PARPi as a novel therapeutic regimen that has the potential to improve CRPC patient outcomes.\n                  <\/jats:p>","DOI":"10.1002\/1878-0261.70183","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:40:43Z","timestamp":1768434043000},"page":"1626-1642","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<scp>PARP<\/scp>\n                    inhibition and pharmacological ascorbate demonstrate synergy in castration\u2010resistant prostate cancer"],"prefix":"10.1002","volume":"20","author":[{"given":"Nicolas","family":"Gordon","sequence":"first","affiliation":[{"name":"Department of Cancer Biology Jefferson University  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T.","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology Jefferson University  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly I.","family":"Richter","sequence":"additional","affiliation":[{"name":"Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery Uniformed Services University of the Health Sciences  Bethesda MD USA"},{"name":"The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.  Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neermala","family":"Poudel Neupane","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology Jefferson University  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Mandigo","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology Jefferson University  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"McCann","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology Jefferson University  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Dylgjeri","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology Jefferson University  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Vasilevskaya","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology Jefferson University  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"McNair","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology Jefferson University  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channing J.","family":"Paller","sequence":"additional","affiliation":[{"name":"Department of Oncology Johns Hopkins University  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wm. Kevin","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Thomas Jefferson University  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Knudsen","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Cancer Center Thomas Jefferson University  Philadelphia PA USA"},{"name":"The American Cancer Society  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2325-4228","authenticated-orcid":false,"given":"Matthew J.","family":"Schiewer","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology Jefferson University  Philadelphia PA USA"},{"name":"Sidney Kimmel Cancer Center Thomas Jefferson University  Philadelphia PA USA"},{"name":"Department of Urology Thomas Jefferson University  Philadelphia PA USA"},{"name":"Department of Pharmacology\/Physiology\/Cancer Biology Thomas Jefferson University  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0335-638X","authenticated-orcid":false,"given":"Ayesha A.","family":"Shafi","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology Jefferson University  Philadelphia PA USA"},{"name":"Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery Uniformed Services University of the Health Sciences  Bethesda MD USA"},{"name":"The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.  Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_2_11_3_1","first-page":"365","article-title":"Mechanisms of resistance in castration\u2010resistant prostate\u00a0cancer (CRPC)","volume":"4","author":"Chandrasekar T","year":"2015","journal-title":"Transl Androl Urol"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014529176"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2013.137"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.73.10.3685"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197909273011303"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2013.5372"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/antiox7070089"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nutres.2012.09.011"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007154"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-017-0044-8"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa5004"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2235-z"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.018"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2017.09.008"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12207"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.291518.116"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03366-0"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03443"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg703"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.4.9.2031"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.06.009"},{"key":"e_1_2_11_25_1","article-title":"Patient\u2010reported outcomes for patients with metastatic castration\u2010resistant prostate cancer and BRCA1\/2 gene alterations: final analysis from the randomized phase 3 MAGNITUDE trial","volume":"7","author":"Rathkopf DE","year":"2024","journal-title":"Eur Urol"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30365-6"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00354"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0811"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01055-3"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115078"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.4103\/iju.iju_307_23"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.10.025"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.001"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.06.004"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0108"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-0381"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1211485"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1877-6"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2017.05.023"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3803"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2014.06.005"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.6.4.387"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/1534735420969812"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01114-x"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.777663"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100199"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440"},{"key":"e_1_2_11_48_1","first-page":"7427","article-title":"Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations","volume":"13","author":"McFarland TR","year":"2021","journal-title":"Am J Transl Res"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2020.12.012"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M002429200"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2021.03.017"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.09.002"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.03.005"}],"container-title":["Molecular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1878-0261.70183","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/1878-0261.70183","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1878-0261.70183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:03:21Z","timestamp":1780506201000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1002\/1878-0261.70183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/1878-0261.70183"],"URL":"https:\/\/doi.org\/10.1002\/1878-0261.70183","archive":["Portico"],"relation":{},"ISSN":["1574-7891","1878-0261"],"issn-type":[{"value":"1574-7891","type":"print"},{"value":"1878-0261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"2025-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}